Stocks · News reference

Barrington Research Maintains Outperform on Lifecore Biomedical, Raises Price Target to $6.5

Jun 16, 2026, 12:27 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 5, 2026, 11:18 AMBenzinga Newsdesk
Lifecore Biomedical Q2 EPS $(0.19) Beats $(0.22) Estimate, Sales $34.200M Beat $32.016M Estimate
Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.22) by 13.64 percent. This is a 24 percent increase over losses of $(0.25) per share from
Read original at benzinga
LFCR
SEC EDGARAug 5, 2026, 11:17 AMSEC EDGAR
8-K filing — LIFECORE BIOMEDICAL, INC. \DE\ (LFCR)
Filed: 2026-08-05 AccNo: 0001005286-26-000032 Size: 4 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgar
LFCR
BenzingaAug 5, 2026, 11:06 AMBenzinga Newsdesk
Lifecore Biomedical Affirms FY2026 Sales Guidance of $120.000M-$125.000M vs $122.176M Est
Lifecore Biomedical (NASDAQ:LFCR) affirms FY2026 sales outlook from $120.000 million-$125.000 million to $120.000 million-$125.000 million vs $122.176 million estimate.
Read original at benzinga
LFCR